MedTrace Logo

Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML

NCT03023384 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 547

Last updated 2017-02-03

No results posted yet for this study

Summary

Create a network of institutions in developing countries that will perform AML diagnosis, risk classification, treatment, supportive care and follow-up evaluation according to a common protocol and will register data using common clinical research forms (CRFs) in a single database and available on the internet.

Conditions

Sponsors & Collaborators

  • International Consortium on Acute Leukemias

    lead OTHER

Principal Investigators

  • Eduardo M Rego, MD · University of Sao Paulo

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2021-01-31
Completion
2022-01-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03023384 on ClinicalTrials.gov